Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-07-11
2006-07-11
Housel, James (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S224100, C435S235100, C435S236000
Reexamination Certificate
active
07074413
ABSTRACT:
Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.
REFERENCES:
patent: 5853735 (1998-12-01), Benejean et al.
patent: WO 01/70932 (2001-09-01), None
Morimoto et al., Journal of Neurovirology, vol. 6, No. 5, pp. 373-381, Oct. 2000.
Allen and Seed (1989)Science243:378-80.
Berg et al. (1995)J. Clin. Invest.96:2339-2347.
Bogdan et al (1991)J. Exp. Med.174:1549-1555.
Carrera et al. (1996)J. Exp. Med.183:515-526.
Cassatella et al. (1989)J. Exp. Med.169:549-567.
Chattergoon et al. (2000)Nat. Biotech.18:974-979.
Chehimi et al. (1994)J. Exp. Med. 179:1361-1366.
Cohn et al. (1946)J. Am. Chem. Soc.68:459-475.
Conzelman (1998)Ann. Rev. Genet.32: 123-162.
Dalrymple et al. (1995)Infect. Immun.63:2262-2268.
D'Andrea et al. (1993)J. Exp. Med.178:1041-1048.
Davidson et al. (1996)J. Exp. Med.184:241-251.
Dietzchold et al. (1983)Proc. Natl. Acad. Sci. USA80:70-74.
Dietzschold et al. (1985)J. Virol.56:12-18.
Dietzchold et al. (1999)Molecular Pathogenesis of Rabies, Abstract Presentation, 10thAnnual Rabies in Americas, Nov. 14-19, San Diego, CA.
Dietzschold et al. (2000)J. Human Virol.3:50-57.
Faber et al. (2002)J. Virol.76:3374-3381.
Finke et al. (2000)J Virol.74:7261-7269.
Fiorentino et al. (1991)J. Immunol.146:3444-3451.
Galelli et al. (2000)J. Neurovirol.6: 359-372.
Gavin et al. (1998)J. Immunol.160:20-23.
Germann et al. (1995)Proc. Natl. Acad. Sci. USA92:4823-4827.
Hale et al. (1988)Lancet2: 1394-1399.
Hart et al. (1995)Immunol.84:536-542.
Hazenbos et al. (1996)Immunity5:181-188.
Heinzel et al. (1993)J. Exp. Med.177:1505-1512.
Howard et al. (1993)J. Exp. Med.177:1205-1208.
Jallet et al. (1999)J. Virol.73:225-233.
Jones et al. (1986)Nature321:522-525.
Karp et al. (1996)Science273:228-231.
Kincy-Cain et al. (1996)Infect. Immun.64:1437-1440.
Kleinveld et al. (1988)Scand. J. Rheumatology75:157-163.
Kothakota et al. (1997)Science278:294-297.
Kunkel et al. (1988)J. Biol. Chem.263:5380-5384.
Lee et al. (1988)J. Chromatography444:141-52.
Leonard et al. (1995)J. Exp. Med.181:381-386.
Malefyt et al. (1991)J. Exp. Med.174:1209-1220.
Malefyt et al. (1991)J. Exp. Med.174:915-924.
Mattner et al. (1996)Eur. J. Immunol.26:1553-1559.
Mebatsion et al. (1995)J. Virol.69(3):1444-1451.
Mebatsion et al. (1996) Proc. Natl. Acad. Sci. USA 93(21):11366-11370.
Morimoto et al. (1996) Proc. Natl. Acad. Sci. USA 93:5653-5658.
Morimoto et al. (1999)J. Virol.73: 510-517.
Morimoto et al. (2000)J. Neurovirol.6:373-381.
Morimoto et al. (2001)Vaccine19:3543-3551.
Muta et al. (1994)Nature368:70-73.
Nathan (1987)J. Clin. Invest.79:319-326.
Noel et al. (1992)J. Infec. Dis.166:178-182.
Oncley et al. (1949)J. Am. Chem. Soc.71:541-550.
Pulmanausahakul et al. (2001)J. Virol.75(22): 10800-10807.
Queen et al. (1989)Proc. Natl. Acad. Sci. USA86:10029-10033.
Reid et al. (1997)J. Immunol.159:970-975.
Reiner et al. (1993)J. Immunol. Methods165:37-46.
Restifo (2000)Curr. Opin. Immunol.12: 597-603
Rovere et al. (1998)J. Immunol.161: 4467-4471.
Sasaki et al. (2001)Nat. Biotech.19: 543-547.
Schnell et al. (1999)Recombinant Rabies Virus as Potential Live-Viral Vaccines for HIV-1, Abstract Presentation, 10thAnnual Rabies in the Americas, Nov. 14-19, San Diego, CA.
Sears et al. (1990)J. Immunol.144:371-78.
Shi et al. (2000)Proc. Natl. Acad. Sci. USA97: 14590-14595.
Sutterwala et al. (1997)J. Exp. Med.185:1977-1985.
Sutterwala et al. (1996)J. Leukocyte Biol.59:883-890.
Takai et al. (1994)Cell76:519-529.
Takai et al. (1996)Nature379:346-349.
Tankersley (1994)Immunol. Reviews139:159-172.
Trembleau et al. (1995)J. Exp. Med.181:817-821.
Trinchieri et al.(1996)J. Leukocyte Biol.59:505-511.
Tripp et al. (1993)Proc. Natl. Acad. Sci. USA90:3725-3729.
Tsunawaki et al. (1988)Nature334:260-262.
Verhoeyen et al. (1988)Science239:1534-1536.
Vialtel et al. (1982)J. Biol. Chem.257:3811-3818.
Virag et al. (1998)Immunol.94: 345-355.
Wiktor (1977)Proc. Natl. Acad. Sci. USA74:334-338.
Wright et al. (1980)Biochem J.187:767-774.
Wysocka et al. (1995)Eur. J. Immunol.25:672-676.
Yan et al. (2001)J. Neurovirol.7: 518-527.
Dietzschold Bernhard
Hooper D. Craig
Rupprecht Charles E.
Schnell Matthias
Hill Myron G.
Housel James
Miller Raymond A.
Pepper Hamilton LLP
Pillion John E.
LandOfFree
Genetically engineered rabies recombinant vaccine for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genetically engineered rabies recombinant vaccine for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetically engineered rabies recombinant vaccine for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3592708